Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02523092 · ClinicalTrials.gov registry record · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
A Phase 4 study of Sarcoidosis, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT02523092 is a Phase 4 study of Sarcoidosis that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 14 participants, below the 2,169-participant average among 21 other Sarcoidosis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02523092, a Phase 4 study of Sarcoidosis, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective is this study is to test whether use of Acthar gel in the context of sarcoidosis will lead to improved symptoms and lung function and correlate with decreased levels of predictive blood biomarkers, like chemokine ligand 9 (CXCL9).
Conditions Studied
Interventions
- DRUG Acthar gel
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2022-11-03 |
| Est. Completion | 2026-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02523092
The ClinicalTrials.gov registry entry for NCT02523092 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,169-participant average among 21 other Sarcoidosis trials with a reported enrollment target (99% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sarcoidosis appearing as the primary indexed condition, and to 1 intervention - of which Acthar gel is the first listed.
NCT02523092 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02523092 about?
NCT02523092 is a clinical study titled "Use of CXCL9 as a Biomarker of Acthar Efficacy". The objective is this study is to test whether use of Acthar gel in the context of sarcoidosis will lead to improved symptoms and lung function and correlate with decreased levels of predictive blood biomarkers, like chemokine ligand 9 (CXCL9).
What is the current status of trial NCT02523092?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 14 participants. The study started on 2022-11-03. Estimated completion is 2026-12.
What conditions does trial NCT02523092 study?
This clinical trial studies the following conditions: Sarcoidosis.
What interventions are being tested in trial NCT02523092?
The interventions under investigation include: Acthar gel (DRUG).
Who is sponsoring clinical trial NCT02523092?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02523092 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Vitamin D Homeostasis in Sarcoidosis
RECRUITING · Phase 4
-
Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension
COMPLETED · Phase 4
-
Quantification & Classification of Inflammatory Cells in Uveitis Using OCT
RECRUITING
-
Cardiovascular Multimodality Imaging Study
RECRUITING
-
Cardiac Sarcoidosis Randomized Trial
RECRUITING · Phase 3
-
Interstitial Lung Disease Research Unit Biobank
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.